










In the format provided by the authors and unedited.

# A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma

Fathima Zumla Cader <sup>1,7,13</sup>, Xihao Hu <sup>2,3,8,13</sup>, Walter L. Goh<sup>4</sup>, Kirsty Wienand<sup>1,9</sup>, Jing Ouyang<sup>1</sup>, Elisa Mandato<sup>1</sup>, Robert Redd <sup>2</sup>, Lee N. Lawton<sup>1</sup>, Pei-Hsuan Chen<sup>5</sup>, Jason L. Weirather <sup>5</sup>, Ron C. J. Schackmann<sup>4,10</sup>, Bo Li <sup>2,3,11</sup>, Wenjiang Ma<sup>1,12</sup>, Philippe Armand <sup>1</sup>, Scott J. Rodig<sup>6</sup>, Donna Neuberg <sup>2</sup>, X. Shirley Liu <sup>2,3,14</sup> ✉ and Margaret A. Shipp <sup>1,14</sup> ✉

---

<sup>1</sup>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. <sup>2</sup>Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA. <sup>3</sup>Harvard T.H. Chan School of Public Health, Boston, MA, USA. <sup>4</sup>Department of Cell Biology, Harvard Medical School, Boston, MA, USA. <sup>5</sup>Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. <sup>6</sup>Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA. <sup>7</sup>Present address: AstraZeneca, City House, Cambridge, UK. <sup>8</sup>Present address: GV20 Therapeutics LLC, Cambridge, MA, USA. <sup>9</sup>Present address: Department of Hematology and Oncology, Göttingen Comprehensive Cancer Center, Göttingen, Germany. <sup>10</sup>Present address: Merus, Utrecht, the Netherlands. <sup>11</sup>Present address: Lyda Hill Department of Bioinformatics, UT Southwestern Medical Center, Dallas, TX, USA. <sup>12</sup>Present address: Clarion Healthcare, Boston, MA, USA. <sup>13</sup>These authors contributed equally: Fathima Zumla Cader, Xihao Hu. <sup>14</sup>These authors jointly supervised this work: X. Shirley Liu, Margaret A. Shipp. ✉e-mail: [xshliu@ds.dfci.harvard.edu](mailto:xshliu@ds.dfci.harvard.edu); [Margaret\\_Shipp@dfci.harvard.edu](mailto:Margaret_Shipp@dfci.harvard.edu)

**Supplementary Table 2.** Mass cytometry antibodies and reporter isotopes used for CyToF Cader et al<sup>31</sup>. Antibodies from Fluidigm/ DVS sciences were conjugated to the isotopes listed. All other antibodies required custom conjugations with a final 0.2mg/ml concentration.

Antibody	Source	Cat No.	Dilution	Clone	Isotopes
CD45	Fluidigm/ DVS sciences	3089003B	1:200	HI30	89Y
PAX5	Biologend	649702	1:50	IH9	113Ind
CD14	Biologend	301801	1:100	M5E2	115Ind
Eomes	eBioscience	Custom	1:50	WD1928	141Pr
Ki-67	BD Biosciences	556003	1:100	B56	142Nd
CD30	BD biosciences	555827	1:100	BerH8	143Nd
CCR5	Fluidigm/ DVS sciences	3144007A	1:100	NP-6G4	144Nd
CD4	Fluidigm/ DVS sciences	3145001B	1:200	RPA-T4	145Nd
CD8a	Fluidigm/ DVS sciences	3146001B	1:200	RPA-T8	146Nd
cParp	BD Biosciences	552597	1:100	F21-852	147Sm
HLA-A/B/C (MHC class I)	Biologend	311402	1:400	W6/32	148Nd
CD25	Fluidigm/ DVS sciences	3149010B	1:200	2A3	149Sm
CD57	Biologend	322325 Discontinued	1:100	HCD57	150Nd
Tim3	BD biosciences	Custom	1:25	7D3	151Eu
PD-L2	Courtesy of G.Freeman, DFCI	N/A		24F.10C12	152Sm
pSTAT1	Fluidigm/ DVS sciences	3153005A	1:100	4a	153Eu
CD163	Fluidigm/ DVS sciences	3154007B	1:100	GHI/61	154Sm
PD-1	Courtesy of G.Freeman, DFCI	N/A	1:50	EH12.2H7	155Gd
B2M	Biologend	316302	1:400	2M2	156Gd
CCR4	Fluidigm/ DVS sciences	3158006B Discontinued	1:100	205410	158Gd
CCR7	Fluidigm/ DVS sciences	3159003A	1:100	G043H7	159Tb
T-bet	Fluidigm/ DVS sciences	3160010B	1:100	4B10	160Gd
PD-L1	Courtesy of G.Freeman, DFCI	N/A	1:50	29E.2A3	161Dy
FoxP3	Fluidigm/ DVS sciences	3162011A	1:100	PCH101	162Dy
CXCR5	R&D	MAB190	1:100	51505	163Dy
CD161	Fluidigm/ DVS sciences	3164069B	1:100	HP-3G10	164Dy
CD45RO	Fluidigm/ DVS sciences	3165011B	1:200	UCHL1	165Ho

Lag3	R&D	MAB23193	1:50	874501	166Er
Granzyme B	Harvard Medical School	N/A	1:200	GB11	167Er
CD73	Fluidigm/ DVS sciences	3168015B	1:100	AD2	168Er
CD33	Fluidigm/ DVS sciences	3169010B	1:100	WM53	169Tm
CD3	Fluidigm/ DVS sciences	3170001B	1:200	UCH T 1	170Er
CD68	Fluidigm/ DVS sciences	3171011B	1:100	Y1/82a	171Yb
phosphoS6	Cell Signaling Technologies	Custom	1:200	D57.2.2E	172Yb
IRF4	Biolegend	646402	1:100	IRF4.3E4	173Yb
HLA-DR/DP/DQ (MHC class II)	Biolegend	361702	1:400	Tu39	174Yb
CD15	Biolegend	301902	1:100	HI98	175Lu
CD56	BD Biosciences	555514	1:100	B159	176Yb
CD16	Fluidigm/ DVS sciences	3209004B	1:100	3G8	209Bi

**Supplementary Table 3.** The target antigens, antibody clones, and dilutions used in Multiplex Immunofluorescence.

Antigen	Antibody dilution	Clone	Ref#	Lot#	Manufacturer	Opal Fluorochrome
CD3	1:750	Poly	A0452	20068607	Dako	650
CD4	1:250	4B12	M7310	20061090	Dako	520
CD68	1:2000	PGM1	M0876	20024189	Dako	620
PAX5	1:100	24/PAX5	610863	9017823	BD Biosciences	570
GZMB	1:100	Grb-7	M7235	20036875	Dako	540